Antonio Pablo Gámez García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Pablo Gámez García has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Cruz-Utrilla
Hospital Universitario 12 de Octubre
1 shared publication - Alicia de Pablo Gafas
Pulmonology Department Hospital Universitario 12 De Octubre Instituto De Investigación Hospital 12 De Octubre (i+12) Madrid Spain
1 shared publication Carlos Andrés
Pulmonology Department Hospital Universitario 12 De Octubre Instituto De Investigación Hospital 12 De Octubre (i+12) Madrid Spain
1 shared publication- Christian Matek
Institute of Pathology, Universitätsklinikum Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Erlangen Germany
1 shared publication Christiane Kuempers
1 shared publication- Clara Salas
Universidad Autónoma de Madrid
1 shared publication
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Artificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
BackgroundPathologic response (PR), expressed as the percentage of residual viable tumor (%RVT), has emerged as a surrogate endpoint after neoadjuvant chemoimmunotherapy in non–small cell lung cancer (NSCLC). However, PR assessment remains subject to interobserver variability and is insufficiently standardized across institutions and clinical trials. We hypothesized that artificial intelligence (AI)-based %RVT scoring would be concordant with expert manual assessment and consistent across real-world, multi-scanner cohorts.Materials and methodsFour retrospective NSCLC cohorts treated with neoadjuvant chemoimmunotherapy and surgery were analyzed. The internal cohort included 38 patients; three external cohorts from China, Germany, and Spain contributed 97 additional patients. Weighted consensus manual %RVT served as the reference standard for benchmarking an AI algorithm. Discordant cases were interrogated for algorithmic bias.ResultsOverall, 135 patients and 1,344 primary-tumor H&E slides were evaluable. Concordance between AI-based and manual assessment was at least moderate across all cohorts. For major pathologic response (MPR) classification, the AI algorithm achieved a pooled accuracy of 91% (95% CI, 85–95), sensitivity of 90% (82–95), specificity of 93% (81–99), and an area under the curve ≥0.95 in all cohorts. Discordant classifications occurred in 8.9% of cases and were mainly attributable to stromal underrepresentation and misclassification of non-neoplastic elements.ConclusionsAI-based %RVT scoring was concordant with expert pathologist consensus and consistent across real-world, multicenter, multi-scanner cohorts, with most algorithmic errors mirroring those encountered in human practice. By providing explainable %RVT grounded in international recommendations, our framework may facilitate harmonization of PR assessment for perioperative therapies.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessArtificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
BackgroundPathologic response (PR), expressed as the percentage of residual viable tumor (%RVT), has emerged as a surrogate endpoint after neoadjuvant chemoimmunotherapy in non–small cell lung cancer (NSCLC). However, PR assessment remains subject to interobserver variability and is insufficiently standardized across institutions and clinical trials. We hypothesized that artificial intelligence (AI)-based %RVT scoring would be concordant with expert manual assessment and consistent across real-world, multi-scanner cohorts.Materials and methodsFour retrospective NSCLC cohorts treated with neoadjuvant chemoimmunotherapy and surgery were analyzed. The internal cohort included 38 patients; three external cohorts from China, Germany, and Spain contributed 97 additional patients. Weighted consensus manual %RVT served as the reference standard for benchmarking an AI algorithm. Discordant cases were interrogated for algorithmic bias.ResultsOverall, 135 patients and 1,344 primary-tumor H&E slides were evaluable. Concordance between AI-based and manual assessment was at least moderate across all cohorts. For major pathologic response (MPR) classification, the AI algorithm achieved a pooled accuracy of 91% (95% CI, 85–95), sensitivity of 90% (82–95), specificity of 93% (81–99), and an area under the curve ≥0.95 in all cohorts. Discordant classifications occurred in 8.9% of cases and were mainly attributable to stromal underrepresentation and misclassification of non-neoplastic elements.ConclusionsAI-based %RVT scoring was concordant with expert pathologist consensus and consistent across real-world, multicenter, multi-scanner cohorts, with most algorithmic errors mirroring those encountered in human practice. By providing explainable %RVT grounded in international recommendations, our framework may facilitate harmonization of PR assessment for perioperative therapies.
- 2 March 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Impact of Pulmonary Veno‐Occlusive Disease on Posttransplant Survival in Pulmonary Hypertension
Introduction: Pulmonary veno‐occlusive disease (PVOD) is a rare but severe form of pulmonary arterial hypertension (PAH), characterized by poor response to medical therapy. Lung transplantation is often the only therapeutic alternative. Methods: We analyzed a retrospective cohort of 58 patients with group 1 PAH who underwent lung transplantation between 2011 and 2024. Baseline characteristics, perioperative complications, and survival were compared between patients with and without PVOD. Statistical methods included descriptive analysis, Kaplan–Meier survival curves, log‐rank tests, and Cox regression. Results: Among the 58 patients, 21 (36.2%) had a diagnosis of PVOD before transplantation. PVOD patients were younger (median age 39.8 vs. 43.1 years, p = 0.03), had lower DLCO (32% vs. 66%, p < 0.001), shorter six‐minute walk distance (300 vs. 430 m, p < 0.001), and a higher COMPERA 2.0 four‐strata risk score (median 3 vs. 2, p = 0.035) tan non‐PVOD patients. Hemodynamically, PVOD patients showed lower systolic pulmonary artery pressure (78 vs. 98 mmHg, p = 0.038), lower pulmonary vascular resistance (9.2 vs. 10.6 Wood units, p = 0.03), and lower right atrial pressure (6.5 vs. 11.5 mmHg, p = 0.003). Time from diagnosis to transplantation was significantly shorter (23.8 vs. 69.6 months, p < 0.001), and extracorporeal membrane oxygenation (ECMO) as bridge to transplantation was more frequent (23.8% vs. 2.7%, p = 0.011). Survival did not differ significantly between groups (log‐rank p = 0.657). Postoperative need for non‐invasive ventilation (NIV) was independently associated with mortality (HR 3.15; 95% CI 1.00–9.83; p = 0.042). Conclusions: Lung transplantation in PVOD patients results in survival comparable to other group 1 PAH subtypes. Postoperative need for NIV identifies patients at higher risk of mortality.
- 2 March 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (3)
Impact of Pulmonary Veno‐Occlusive Disease on Posttransplant Survival in Pulmonary Hypertension
Introduction: Pulmonary veno‐occlusive disease (PVOD) is a rare but severe form of pulmonary arterial hypertension (PAH), characterized by poor response to medical therapy. Lung transplantation is often the only therapeutic alternative. Methods: We analyzed a retrospective cohort of 58 patients with group 1 PAH who underwent lung transplantation between 2011 and 2024. Baseline characteristics, perioperative complications, and survival were compared between patients with and without PVOD. Statistical methods included descriptive analysis, Kaplan–Meier survival curves, log‐rank tests, and Cox regression. Results: Among the 58 patients, 21 (36.2%) had a diagnosis of PVOD before transplantation. PVOD patients were younger (median age 39.8 vs. 43.1 years, p = 0.03), had lower DLCO (32% vs. 66%, p < 0.001), shorter six‐minute walk distance (300 vs. 430 m, p < 0.001), and a higher COMPERA 2.0 four‐strata risk score (median 3 vs. 2, p = 0.035) tan non‐PVOD patients. Hemodynamically, PVOD patients showed lower systolic pulmonary artery pressure (78 vs. 98 mmHg, p = 0.038), lower pulmonary vascular resistance (9.2 vs. 10.6 Wood units, p = 0.03), and lower right atrial pressure (6.5 vs. 11.5 mmHg, p = 0.003). Time from diagnosis to transplantation was significantly shorter (23.8 vs. 69.6 months, p < 0.001), and extracorporeal membrane oxygenation (ECMO) as bridge to transplantation was more frequent (23.8% vs. 2.7%, p = 0.011). Survival did not differ significantly between groups (log‐rank p = 0.657). Postoperative need for non‐invasive ventilation (NIV) was independently associated with mortality (HR 3.15; 95% CI 1.00–9.83; p = 0.042). Conclusions: Lung transplantation in PVOD patients results in survival comparable to other group 1 PAH subtypes. Postoperative need for NIV identifies patients at higher risk of mortality.